Hi, my name is Tappan Khadiyya. I'm currently a professor in the Department of Leukemia at MD Anderson Cancer Center in Houston. I'm here at the ASH meeting, delighted to be here. I'm going to talk to you about one of our abstracts, one of our research data in patients with acute myeloid leukemia. So we have several abstracts during this ASH focusing on the treatment of patients who are older or unfit for intensive chemotherapy. One of those is a combination we've used before and have published on before, but now we have more patients with longer follow-up. It's a regimen of cladribine plus lotus siteribine plus venetoclax in patients newly diagnosed with AML who are age 60 or older. So those patients who may not be able to tolerate the most intensive chemotherapy that we give for leukemia. In that setting, we found an excellent response rate of about 80 percent. So eight out of ten people went to complete remission. So eight out of ten of those patients having negative minimal residual disease, so really, really deep remissions with a median overall survival of about 50 months. So that's actually better than anything that we've seen in older patients with newly diagnosed AML and hopefully we can continue on that study. We found that certain subgroups such as those with NPM1 mutated or IDH1 or IDH2 mutated and RUNX1 mutated AML respond particularly well. And there's also subgroup patients with RAS mutations, which may not benefit as much with the chemotherapy combination of HMA and venetoclax, but we're seeing excellent responses and good long-term outcomes with this regimen. So I look forward to seeing how we do as the follow-up continues going forward.
HealthTree • December 11, 2023